Annual Financial Report and notice of AGM

23 April 2014

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Company update

Annual Financial Report for the year ended 31 December 2013 and notice of AGM

Plethora Solutions Holdings plc (AIM:PLE) announces that the Company will post the Annual Report and Accounts to shareholders on 25 April 2014 together with the notice of the Annual General Meeting which will take place at 10.00 am on 10 June 2014 at the offices of Daniel Stewart, Becket House, 36 Old Jewry, London, ECR 8DD.

The Annual Report and Accounts for the year ended 31 December 2013 and Notice of AGM are now available on the Company's website at www.plethorasolutions.co.uk.

-Ends-

Enquiries:

About Plethora:

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk 

Plethora is focussed on seeking to launch PSD502 for the treatment of premature ejaculation.

About PSD502 & Premature Ejaculation:

PSD502 is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. The Company anticipates launch in 2014.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.